Skip to main content

Table 4 Proteins detected with 2D-nanoLC-MS/MS in 14 pairs or more

From: Searching for early breast cancer biomarkers by serum protein profiling of pre-diagnostic serum; a nested case-control study

   Pairs* Weighted ratio Random fixed
effects model
Protein Name Function n Mean 95%CI p-value
Vitronectin   16 1.06 0.99-1.13 .07
Transthyretin   15 0.98 0.88-1.09 .71
Alpha-1B-glycoprotein   20 1.03 0.99-1.07 .17
Alpha-2-macroglobulin Proteinase inhibitor 20 0.94 0.88-1.00 .04
Afamin Serum transport protein 17 1.10 1.02-1.18 .02
AMBP protein   18 1.04 0.97-1.12 .26
Apolipoprotein A-I   20 1.04 0.97-1.12 .25
Apolipoprotein A-II   20 0.98 0.91-1.06 .61
Apolipoprotein A-IV   20 1.05 0.95-1.18 .32
Apolipoprotein B-100   20 1.06 0.99-1.12 .08
Complement C3 (Fragment)   20 1.02 0.98-1.06 .34
Isoform 1 of Complement factor H   18 1.02 0.97-1.07 .39
Ceruloplasmin Acute phase reactant 20 0.94 0.89-0.99 .03
Hemopexin   20 0.96 0.90-1.02 .17
Histidine-rich glycoprotein   20 0.96 0.89-1.04 .30
Inter-alpha trypsin inhibitor heavy chain H1   16 1.00 0.94-1.07 .89
Alpha-1-acid glycoprotein 2   16 1.00 0.93-1.08 .91
Inter-alpha (Globulin) inhibitor H2   18 0.96 0.89-1.04 .33
Orosomucoid 1   20 1.06 0.98-1.14 .16
Alpha-1-antichymotrypsin   19 1.00 0.92-1.08 .94
B-factor, properdin   18 0.99 0.94-1.05 .76
Plasminogen   18 0.98 0.90-1.07 .69
Alpha-2-HS-glycoprotein   18 1.00 0.94-1.07 .88
Beta-2-glycoprotein 1   18 0.99 0.92-1.05 .66
C4B1   16 0.99 0.93-1.05 .74
Prothrombin (Fragment)   16 0.98 0.88-1.10 .76
Apolipoprotein E Lipid metabolism 16 1.13 1.01-1.26 .04
Apolipoprotein C-I   14 1.02 0.94-1.12 .57
13 kDa protein   14 1.03 0.92-1.16 .55
Isoform LMW of Kininogen-1   18 1.06 0.98-1.14 .13
Isoform 1 of inter-alpha trypsin inhibitor heavy chain H4 Acute phase reactant 16 1.08 1.03-1.14 <.01
Vitamin D-binding protein   20 1.03 0.99-1.07 .17
  1. 95%CI: 95% confidence interval; * Number of pairs in which a ratio could be determined and a EF could be calculated; Ratio case/control